CR20190517A - Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton - Google Patents

Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton

Info

Publication number
CR20190517A
CR20190517A CR20190517A CR20190517A CR20190517A CR 20190517 A CR20190517 A CR 20190517A CR 20190517 A CR20190517 A CR 20190517A CR 20190517 A CR20190517 A CR 20190517A CR 20190517 A CR20190517 A CR 20190517A
Authority
CR
Costa Rica
Prior art keywords
benzoazepine
analogues
tyrosine kinase
inhibiting agents
bruton tyrosine
Prior art date
Application number
CR20190517A
Other languages
English (en)
Spanish (es)
Inventor
Brian T Hopkins
Bin Ma
Matthew Peterson
Daniel B Patience
Isaac Marx
Fengmei Zheng
Joseph P Lyssikatos
Robin Prince
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CR20190517A publication Critical patent/CR20190517A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR20190517A 2017-04-14 2018-04-13 Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton CR20190517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485745P 2017-04-14 2017-04-14
PCT/US2018/027415 WO2018191577A1 (en) 2017-04-14 2018-04-13 Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
CR20190517A true CR20190517A (es) 2020-02-13

Family

ID=62092333

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20190517A CR20190517A (es) 2017-04-14 2018-04-13 Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CR20230539A CR20230539A (es) 2017-04-14 2019-04-13 ANÁLOGOS DE BENZOAZEPINA COMO AGENTES INHIBIDORES DE LA TORISINA CINASA DE BRUTON (Divisional 2019-0517)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20230539A CR20230539A (es) 2017-04-14 2019-04-13 ANÁLOGOS DE BENZOAZEPINA COMO AGENTES INHIBIDORES DE LA TORISINA CINASA DE BRUTON (Divisional 2019-0517)

Country Status (36)

Country Link
US (5) US10227341B2 (https=)
EP (2) EP3609886B1 (https=)
JP (3) JP7145874B2 (https=)
KR (3) KR20250140646A (https=)
CN (2) CN117567453A (https=)
AR (2) AR111594A1 (https=)
AU (3) AU2018253209B2 (https=)
CA (1) CA3058774A1 (https=)
CL (1) CL2019002900A1 (https=)
CO (1) CO2019012571A2 (https=)
CR (2) CR20190517A (https=)
DK (1) DK3609886T3 (https=)
EA (1) EA201992354A1 (https=)
ES (1) ES2975769T3 (https=)
FI (1) FI3609886T3 (https=)
HR (1) HRP20240361T1 (https=)
HU (1) HUE066253T2 (https=)
IL (3) IL269933B (https=)
JO (1) JOP20190233B1 (https=)
LT (1) LT3609886T (https=)
MA (1) MA50013B1 (https=)
MD (1) MD3609886T2 (https=)
MX (1) MX2023000812A (https=)
PE (2) PE20200740A1 (https=)
PH (1) PH12019502334A1 (https=)
PL (1) PL3609886T3 (https=)
PT (1) PT3609886T (https=)
RS (1) RS65386B1 (https=)
SA (1) SA519410292B1 (https=)
SG (1) SG11201909224QA (https=)
SI (1) SI3609886T1 (https=)
SM (1) SMT202400166T1 (https=)
TW (2) TWI846229B (https=)
UA (1) UA127347C2 (https=)
WO (1) WO2018191577A1 (https=)
ZA (1) ZA202306172B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014362231B2 (en) 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
IL269933B (en) 2017-04-14 2022-07-01 Biogen Ma Inc Benzozapine analogues as inhibitors for proton tyrosine kinase
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
US12240838B2 (en) 2019-05-15 2025-03-04 Biogen Ma Inc. Inhibiting agents for Bruton's tyrosine kinase
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
CN118804915A (zh) 2021-11-10 2024-10-18 渤健马萨诸塞州股份有限公司 Btk抑制剂
KR20240128831A (ko) 2021-12-30 2024-08-27 베이진 스위찰랜드 게엠베하 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
EP2209786B1 (en) 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 6員芳香環含有化合物
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
EP3689878B1 (en) 2011-07-19 2021-10-06 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
AU2014362231B2 (en) * 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US10253023B2 (en) * 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
IL269933B (en) 2017-04-14 2022-07-01 Biogen Ma Inc Benzozapine analogues as inhibitors for proton tyrosine kinase

Also Published As

Publication number Publication date
WO2018191577A1 (en) 2018-10-18
JP2020516659A (ja) 2020-06-11
PL3609886T3 (pl) 2024-05-13
DK3609886T3 (da) 2024-03-18
JOP20190233A1 (ar) 2019-10-02
US20200239459A1 (en) 2020-07-30
PH12019502334A1 (en) 2020-09-21
HRP20240361T1 (hr) 2024-06-07
MA50013B1 (fr) 2024-05-31
IL269933B (en) 2022-07-01
CN110621670B (zh) 2023-09-15
EA201992354A1 (ru) 2020-03-10
SG11201909224QA (en) 2019-11-28
ZA202306172B (en) 2024-11-27
CA3058774A1 (en) 2018-10-18
IL294175B1 (en) 2024-12-01
JP7145874B2 (ja) 2022-10-03
JOP20190233B1 (ar) 2024-04-18
IL269933A (https=) 2019-11-28
BR112019021399A2 (pt) 2020-04-28
AU2022218560B2 (en) 2024-04-04
US10227341B2 (en) 2019-03-12
SI3609886T1 (sl) 2024-05-31
SA519410292B1 (ar) 2023-03-12
AR129632A2 (es) 2024-09-11
US20180297992A1 (en) 2018-10-18
AU2018253209B2 (en) 2022-06-02
MX2023000812A (es) 2023-02-27
UA127347C2 (uk) 2023-07-26
JP2025020247A (ja) 2025-02-12
MD3609886T2 (ro) 2024-07-31
CR20230539A (es) 2024-04-08
PT3609886T (pt) 2024-04-11
JP7778206B2 (ja) 2025-12-01
US10189829B2 (en) 2019-01-29
CO2019012571A2 (es) 2020-01-17
EP4249071A3 (en) 2024-01-24
CL2019002900A1 (es) 2020-01-24
EP3609886B1 (en) 2024-02-07
KR20250140646A (ko) 2025-09-25
RS65386B1 (sr) 2024-04-30
US20210340135A1 (en) 2021-11-04
IL294175A (en) 2022-08-01
JP7581294B2 (ja) 2024-11-12
US11427577B2 (en) 2022-08-30
KR20190139926A (ko) 2019-12-18
TWI846229B (zh) 2024-06-21
SMT202400166T1 (it) 2024-07-09
TW202315870A (zh) 2023-04-16
EP4249071A2 (en) 2023-09-27
MA50013A (fr) 2020-07-08
JP2022180498A (ja) 2022-12-06
FI3609886T3 (fi) 2024-03-26
LT3609886T (lt) 2024-04-10
PE20200740A1 (es) 2020-07-24
KR102862996B1 (ko) 2025-09-22
HUE066253T2 (hu) 2024-07-28
EP3609886A1 (en) 2020-02-19
ES2975769T3 (es) 2024-07-15
TWI790227B (zh) 2023-01-21
AU2018253209A1 (en) 2019-10-31
IL316713A (en) 2024-12-01
AU2022218560A1 (en) 2022-09-15
US11858926B2 (en) 2024-01-02
TW201841909A (zh) 2018-12-01
AR111594A1 (es) 2019-07-31
KR20230164247A (ko) 2023-12-01
US10961237B2 (en) 2021-03-30
KR102607900B1 (ko) 2023-11-29
IL294175B2 (en) 2025-04-01
CN117567453A (zh) 2024-02-20
US20180362522A1 (en) 2018-12-20
US20230147490A1 (en) 2023-05-11
NZ757929A (en) 2025-10-31
AU2024204241A1 (en) 2024-07-11
PE20240930A1 (es) 2024-04-30
CN110621670A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
MX2020008024A (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP18092481A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
MX2022002976A (es) Inhibidores selectivos de jak1.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
EA201792116A1 (ru) Ингибитор янус-киназы
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2019013308A (es) Composiciones y compuestos terapeuticos, y metodos para su uso.
MX374724B (es) Derivados de carbazol.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
MX2018004664A (es) Antagonistas de ep4.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2020001089A1 (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).